Biologics Pipelines: Who Has the Next Promising Monoclonal Antibodies?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Trends and Their Implications for Stakeholders
• Evolving Biologics Market
• Alzheimer' s Disease and Anti-Amyloid Antibodies
  • Elan/Wyeth' s AAB-001 (Bapineuzumab)
  • MAbs in Early-Stage Clinical Development for Alzheimer' s Disease
• Anti-Integrin Antibodies
  • Biogen Idec/Elan' s Tysabri (Natalizumab)
  • Anti-Integrin Antibodies in Early-Stage Clinical Development
    • Biogen Idec/PDL BioPharma' s M-200 (Volociximab)
    • Johnson & Johnson/Centocor/Medarex' s CNTO-95
    • Millennium' s MLN-0002
• Selective T-Cell Co-Stimulation Antagonists
  • Superagonist Debacle
  • Bristol-Myers Squibb' s Orencia (Abatacept)
  • Three Phase III Contenders
    • Bristol-Myers Squibb' s LEA29Y (Belatacept)
    • Medarex/Bristol-Myers Squibb' s MDX-010 (Ipilimumab)
    • Pfi zer' s CP-675,206 (Tremelimumab)
• Complement and Complement Receptor Antibodies
  • HIV Antibody Therapies
  • Blocking Immune Cell Migration to Infl ammation Sites
  • Cytotoxicity-Enhanced CCR4 Antibody
• B-Cell-Targeted Therapies: Anti-CD20 Antibodies
  • Biogen Idec/Genentech/Roche/Chugai/Zenyaku' s Rituxan/MabThera (Rituximab)
  • Anti-CD20 Antibodies in Clinical Development
    • Biogen Idec/Genentech/Roche' s R-1594/PRO-70769 (Ocrelizumab)
    • GlaxoSmithKline/Genmab' s HuMax-CD20 (Ofatumumab)
    • Immunomedics' IMMU-106 (Veltuzumab)
  • Next-Generation Engineered Antibodies
  • Radioimmunotherapy
• T-Cell-Targeted Therapies
  • Anti-CD3 Antibodies
    • Agents in Development for Recent-Onset Type 1 Diabetes
    • Agents in Development for Infl ammatory Bowel Diseases
  • CD4-Targeting Antibodies
• Novel Interleukin-6 Receptor Antagonist Class
• Tumor Necrosis Factor-Alpha Inhibitors
• EGFR-Targeted Therapies
  • Bristol-Myers Squibb/ImClone Systems /Merck Serono' s Erbitux (Cetuximab)
  • Amgen' s Vectibix (Panitumumab)
  • EGFR Antagonists in Clinical Development
    • Oncoscience/YM Bioscience/Daiichi Sankyo' s TheraCIM h-R3/Theraloc (Nimotuzumab)
    • Genmab' s HuMax-EGFR (Zalutumumab)
    • Merck Serono/Takeda' s EMD-72000 (Matuzumab)
    • Bristol-Myers Squibb/ImClone Systems' IMC-11F8
• Anti-VEGF Angiogenesis Inhibitors
  • Genentech/Roche/Chugai' s Bevacizumab (Avastin)
  • Drug Resistance and Combination Therapies
  • Genentech/Novartis' s Lucentis (Ranibizumab)
  • ThromboGenics/BioInvent' s TB-403
• Four Developing Trends
  • Trend 1
  • Trend 2
  • Trend 3
  • Trend 4

Tables:

• 1. Alzheimer' s Disease and Anti-Amyloid Antibodies
• 2. Anti-Integrin Antibodies
• 3. Selective T-Cell Co-Stimulation Antagonists
• 4. Select Complement Receptor Antibodies
• 5. Anti-CD20 Antibodies
• 6. Anti-CD3 Antibodies
• 7. Anti-CD4 Antibodies
• 8. Tumor Necrosis Factor Alpha (TNF-α) Antibodies
• 9. Anti-EGFR Antibodies
• 10. Anti-VEGF Angiogenesis Inhibitors

Figures:

• 1. Evolving Pharmaceutical Market Segments Based on Technology, 2000-2012
• 2. Top-Selling Monoclonal Antibodies, 2007
• 3. Amyloid Plaques and Neurofi brillary Tangles in Alzheimer' s Disease
• 4. Mechanisms of T-Cell Co-Stimulation
• 5. The Life Cycle of HIV-1
• 6. EGFR Family
• 7. The Angiogenic Process
• 8. TNF-Alpha Inhibitors, 2006-2016: Market Share

Decision Resources, Inc., Analysts Featured

• Madhuri Borde, Ph.D., analyst, Immune and Infl ammatory Disorders
• Sylvia Eash, Ph.D., analyst, Infectious Disease
• Clair Gricks, Ph.D., analyst, Onkos
• Neil Grubert, M.A., director of pricing and reimbursement, Spectrum, Pharmacoeconomics, Pricing, and Reimbursement
• Bethany A. Kiernan, Ph.D., analyst, Cognos
• Joanna Kim, M.Ed., analyst, Immune and Infl ammatory Disorders
• Nitasha Manchanda, Ph.D., analyst, Cognos
• Jennifer Moniz Carpenter, M.B.A., program manager, Spectrum, Therapy Markets and Emerging Technologies
• Mohamed Muhsin, M.Sc., analyst, Onkos
• Alice von Loesecke, Ph.D., senior director, New Products